ClinicalTrials.gg
CompletedNCT04424251Updated Aug 26, 2024

Efficacy and Safety of HSK21542 in Inducing Postoperative Analgesia in Undergoing Elective Laparoscopic Surgery

A Phase 2 interventional study of Experimental: stage I:HSK21542 0.4 μg/kg and Experimental: stage I:HSK21542 1 μg/kg in Analgesia, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-08-26.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, two-stage phase II clinical study. The main objective is to evaluate the efficacy and safety of HSK21542 injection and explore the recommended dose and administration frequency for subsequent Phase II studies in conjunction with the pharmacodynamic (PD) and pharmacokinetic (PK) characteristics.

02

Conditions studied

  • Analgesia
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 ≤ age ≤ 70 years old, with no gender requirement
  2. (ASA) Class I-II
  3. 18 kg/m\^2 ≤ ≤ 40 kg/m\^2
  4. Subjects undergoing elective laparoscopic surgery under general anesthesia with an expected surgery duration of 1-5 h (inclusive)
  5. Agree to participate in this trial and voluntarily sign the form;

Exclusion criteria

Exclusion Criteria:

  1. History of allergy to opioids, such as urticaria, or allergic to the intraoperative anesthetics prescribed in the protocol;
  2. History or evidence of any one of the following diseases prior to screening:

    1. History of cardiovascular diseases: Uncontrolled hypertension (systolic blood pressure [SBP] ≥ 170 mmHg and/or diastolic blood pressure [DBP] ≥ 105 without antihypertensive treatment, or SBP > 160 mmHg and/or DBP > 100 mmHg despite antihypertensive treatment), aneurysm, severe arrhythmia, heart failure, Adams-Stokes syndrome, (NYHA) Class ≥ III, severe superior vena caval syndrome, pericardial effusion, acute myocardial ischemia, unstable angina, myocardial infarction in the last 6 months before screening, history of tachycardia/bradycardia requiring medication, and II-III degree atrioventricular block (excluding patients with pacemakers);
    2. History of respiratory disorder: Severe , acute exacerbation of chronic obstructive pulmonary disease, severe bronchostenosis, throat mass, history of (bronchial) tracheoesophageal fistula or airway tear, and severe respiratory tract infection in the last 2 weeks before screening;
    3. History of disorders in the nervous and psychiatric system: History of craniocerebral injury, possible convulsions, intracranial hypertension, cerebral aneurysms, and history of cerebrovascular accidents; history of schizophrenia, mania, mental aberration, long-term use of psychotropic drugs, and cognitive disorder; history of depression, anxiety, and epilepsy, etc.;
    4. Underwent major surgery within 3 months before screening and was judged by the investigator to have potential effect on the postoperative pain evaluation;
  3. Any of the following airway management risks during screening:

    1. Acute asthma attacks;
    2. Sleep apnea syndrome;
    3. History or family history of malignant hyperthermia;
    4. History of failed tracheal intubation;
    5. Difficult airway (modified Mallampati score ≥ III) as determined by the investigator;
  4. In receipt of any of the following drugs or therapies during the screening period:

    1. The time between randomization and the last dose of opioid or non-opioid (such as acetaminophen, aspirin [daily dose of > 100 mg], indomethacin, diclofenac, parecoxib sodium and other non-steroidal anti-inflammatory drugs) analgesics is shorter than 5 half-lives of the drug or the duration of drug efficacy (whichever is longer);
    2. Continuous use of opioid analgesics for more than 10 days for any reason within 3 months before screening;
    3. Use of drugs that affect the analgesic effect within 14 days before randomization, including but not limited to: Sedative hypnotics (benzodiazepines [triazolam, diazepam, midazolam, etc.], non-benzodiazepines [zolpidem, zopiclone, zaleplon, etc.]), sedative anesthetics (sevoflurane, anesthesia ether, nitrous oxide, thiopental, ketamine, etomidate, etc.), (dexamethasone hydrochloride , methylprednisolone, etc.), anti-epilepsy drugs (carbamazepine, sodium valproate, etc.), anxiolytics (carbamazepine, diazepam, etc.), antidepressants (imipramine, amitriptyline, etc.), and Chinese herbal medicines or Chinese patent medicines with analgesic and sedative effects;
    4. Expected to receive anti-tumor drugs and treatments during the period from 14 days before randomization to the end of the follow-up period, including but not limited to chemotherapeutic drugs, targeted drugs, and Chinese herbal medicines.
    5. The time between randomization and the last use of diuretics and compound drugs containing diuretic components is shorter than 5 half-lives of the drug or the duration of drug efficacy (whichever is longer);
  5. Laboratory test parameters meet one of the following criteria in the screening period and is confirmed by retests:

    1. White blood cell count \< 3.0 x 10\^9/L;
    2. count \< 80 x 10\^9/L;
    3. \<70 g/L;
    4. > 1.5 x ;
    5. Activated partial thromboplastin time > 1.5 x ULN;
    6. and/or aspartate aminotransferase > 2 x ULN;
    7. Total > 1.5 x ULN;
    8. Blood creatinine > 1.5 x ULN;
    9. Fasting blood glucose ≥ 11.1 mmol/L;
  6. Without oxygen supplement during the screening period, the pulse oxygen saturation is \< 92%;
  7. During the screening period, the virological examination for surface antigen (HBsAg), antibody (HCVAb), treponema pallidum antibody, or (HIV) antibody is positive;
  8. History of drug abuse, narcotics use and/or alcohol abuse within 3 months before screening. Alcohol abuse is defined as > 2 units of alcohol consumption per day (1 unit = 360 mL of beer containing 5% alcohol, 45 mL of liquor containing 40% alcohol, or 150 mL of wine);
  9. Donated or lost ≥ 400 mL of blood within 3 months before screening;
  10. Participated in any drug clinical trials within 3 months before screening (defined as the administration of the product or placebo);
  11. Women who are pregnant or breastfeeding; fertile women or men who are unwilling to use during the trial; subjects who are planning pregnancy within 3 month after the completion of the trial (including male subjects);
  12. Subjects determined by the investigator to be unsuitable for participating in this clinical study for any other reason.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    stage I:HSK21542 0.4 μg/kg

    Preoperative:0.4 μg/kg Postoperative:0.2 μg/kg; intravenous injection

    Drug: Experimental: stage I:HSK21542 0.4 μg/kg

  • Experimental
    stage I:HSK21542 1 μg/kg

    Preoperative:1 μg/kg Postoperative:0.5 μg/kg;intravenous injection

    Drug: Experimental: stage I:HSK21542 1 μg/kg

  • Experimental
    stage I:HSK21542 0.5μg/kg

    Postoperative: 0.5μg/kg;intravenous injection

    Drug: Experimental: stage I:HSK21542 0.5μg/kg

  • Experimental
    stage I:HSK21542 1μg/kg

    Postoperative: 1μg/kg;intravenous injection

    Drug: Experimental: stage I:HSK21542 1μg/kg

  • Experimental
    stage II:HSK21542 0.5μg/kg

    Postoperative: 0.5μg/kg;intravenous injection

    Drug: Experimental: stage II:HSK21542 0.5μg/kg

  • Experimental
    stage II:HSK21542 1μg/kg

    Postoperative: 1μg/kg;intravenous injection

    Drug: Experimental: stage II:HSK21542 1μg/kg

  • Placebo comparator
    Postoperative: Placebo

    Placebo;intravenous injection

    Drug: Placebo

Interventions

  • DrugExperimental: stage I:HSK21542 0.4 μg/kg

    Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations

  • DrugExperimental: stage I:HSK21542 1 μg/kg

    Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations

  • DrugExperimental: stage I:HSK21542 0.5μg/kg

    once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

  • DrugExperimental: stage I:HSK21542 1μg/kg

    once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

  • DrugExperimental: stage II:HSK21542 0.5μg/kg

    once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

  • DrugExperimental: stage II:HSK21542 1μg/kg

    once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

  • DrugPlacebo

    once each at 0, 8, and 16 h postoperative, for a total of 3 administrations

06

What researchers measure

Primary outcomes

  1. Sum of Pain Intensity Differences (SPID)

    The time-weighted SPID at rest within 0-24 h after the first postoperative administration in each group

    Time frame: Frome administration until 24 hours after administration

Secondary outcomes

  1. Sum of Pain Intensity Differences (SPID)

    The time-weighted sum of pain intensity differences of the rest pain in each group within 0-12 h after the first postoperative dose

    Time frame: Frome administration until 24 hours after administration

  2. Use of remedial analgesics

    Cumulative dose of remedial analgesics (mg of morphine injection) in each group within 0-12 h and 0-24 h after the first postoperative dose, the percentage of subjects in each group who have not used remedial analgesics, and the time to start using remedial analgesics

    Time frame: Frome administration until 24 hours after administration

  3. Pain Intensity Differences(PID)

    The PID at rest at each scoring time point after the first postoperative administration in each group

    Time frame: Frome administration until 24 hours after administration

  4. The proportion of subjects with a NRS of ≤ 3

    The proportion of subjects in each group with a resting pain NRS of ≤ 3 at 12 h and 24 h after the first postoperative dose

    Time frame: Frome administration until 24 hours after administration

  5. Duration of analgesia

    The duration of analgesia after the first postoperative administration in each group

    Time frame: Frome administration until 24 hours after administration

  6. Satisfaction scores on postoperative analgesia

    Subject satisfaction score and investigator satisfaction score on postoperative analgesia at 24 h after the first postoperative administration in each group

    Time frame: Frome administration until 24 hours after administration

07

Study locations

1 site
  • Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Dec 2020, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2020
First posted
Jun 9, 2020
StartActual
Jul 2, 2020
Primary completionActual
Dec 7, 2020
CompletionActual
Jan 5, 2021
Last update
Aug 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04424251
Responsible party
Sponsor
First posted
Jun 9, 2020
Start date
Jul 2, 2020
Primary completion
Dec 7, 2020
Completion
Jan 5, 2021
Last update
Aug 26, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion